Auteurs Ballotti R, Bertolotto C
Molecular & cellular oncology Jan 2017
FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells.Auteurs Bourseguin J, Bonet C, Renaud E, Pandiani C, Boncompagni M, Giuliano S, Pawlikowska P, Karmous-Benailly H, Ballotti R, Rosselli F, Bertolotto C
Scientific reports Nov 2016
ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.Auteurs Richard G, Dalle S, Monet MA, Ligier M, Boespflug A, Pommier RM, de la Fouchardière A, Perier-Muzet M, Depaepe L, Barnault R, Tondeur G, Ansieau S, Thomas E, Bertolotto C, Ballotti R, Mourah S, Battistella M, Lebbé C, Thomas L, Puisieux A, Caramel J
EMBO molecular medicine Oct 2016
Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance.Auteurs Cerezo M, Lehraiki A, Millet A, Rouaud F, Plaisant M, Jaune E, Botton T, Ronco C, Abbe P, Amdouni H, Passeron T, Hofman V, Mograbi B, Dabert-Gay AS, Debayle D, Alcor D, Rabhi N, Annicotte JS, Héliot L, Gonzalez-Pisfil M, Robert C, Moréra S, Vigouroux A, Gual P, Ali MMU, Bertolotto C, Hofman P, Ballotti R, Benhida R, Rocchi S
Cancer cell Juil 2016
Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.Auteurs Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P, , Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B
Nature Mar 2016
Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib.Auteurs Lehraiki A, Cerezo M, Rouaud F, Abbe P, Allegra M, Kluza J, Marchetti P, Imbert V, Cheli Y, Bertolotto C, Ballotti R, Rocchi S
Cell discovery Oct 2015
NF1 loss induces senescence during human melanocyte differentiation in an iPSC-based model.Auteurs Larribere L, Wu H, Novak D, Galach M, Bernhardt M, Orouji E, Weina K, Knappe N, Sachpekidis C, Umansky L, Beckhove P, Umansky V, De Schepper S, Kaufmann D, Ballotti R, Bertolotto C, Utikal J
Pigment cell & melanoma research Jul 2015
Is it time to test biguanide metformin in the treatment of melanoma?Auteurs Cerezo M, Tomic T, Ballotti R, Rocchi S
Pigment cell & melanoma research Juin 2014
Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma.Auteurs Fernández-Barral A, Orgaz JL, Baquero P, Ali Z, Moreno A, Tiana M, Gómez V, Riveiro-Falkenbach E, Cañadas C, Zazo S, Bertolotto C, Davidson I, Rodríguez-Peralto JL, Palmero I, Rojo F, Jensen LD, del Peso L, Jiménez B
Neoplasia (New York, N.Y.) Jun 2014
A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.Auteurs Allegra M, Giacchero D, Segalen C, Dumaz N, Butori C, Hofman V, Hofman P, Lacour JP, Bertolotto C, Bahadoran P, Ballotti R
The Journal of investigative dermatology May 2014